Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$269M |
| 2 |
Amazon
AMZN
|
+$242M |
| 3 |
Apple
AAPL
|
+$215M |
| 4 |
Amgen
AMGN
|
+$212M |
| 5 |
Citizens Financial Group
CFG
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$210M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$195M |
| 3 |
iShares GSCI Commodity Dynamic Roll Strategy ETF
COMT
|
+$154M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$127M |
| 5 |
WORK
Slack Technologies, Inc.
WORK
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.58% |
| 2 | Financials | 13.47% |
| 3 | Healthcare | 12.09% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2301
ARKO Corp
ARKO
$505M
| $5.84M | ﹤0.01% |
577,827
+226,210
| +64% | +$2.04M |
|
|
NGM
2302
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $5.79M | ﹤0.01% |
275,246
+93,136
| +51% | +$2.05M |
|
2303
Syndax Pharmaceuticals
SNDX
$1.7B
| $5.78M | ﹤0.01% |
302,527
+32,896
| +12% | +$548K |
|
|
RC
2304
Ready Capital
RC
$294M
| $5.76M | ﹤0.01% |
398,856
+123
| +0% | +$1.86K |
|
2305
Workhorse Group
WKHS
$33.1M
| $5.75M | ﹤0.01% |
251
-9
| -3% | -$272K |
|
2306
Credicorp
BAP
$29.8B
| $5.73M | ﹤0.01% |
51,642
+11,503
| +29% | +$1.25M |
|
2307
OraSure Technologies
OSUR
$277M
| $5.73M | ﹤0.01% |
506,354
+14,328
| +3% | +$157K |
|
2308
Hillman Solutions
HLMN
$1.71B
| $5.71M | ﹤0.01% |
+478,273
| New | +$5.85M |
|
|
AY
2309
DELISTED
Atlantica Sustainable Infrastructure plc Ordinary Shares
AY
| $5.71M | ﹤0.01% |
165,325
+11,923
| +8% | +$452K |
|
2310
Gorman-Rupp
GRC
$2.11B
| $5.69M | ﹤0.01% |
158,956
+20,603
| +15% | +$731K |
|
2311
Banc of California
BANC
$3.11B
| $5.69M | ﹤0.01% |
307,797
-847
| -0.3% | -$14.8K |
|
2312
Invivyd
IVVD
$202M
| $5.66M | ﹤0.01% |
+134,058
| New | +$4.98M |
|
2313
PureCycle Technologies
PCT
$1.41B
| $5.66M | ﹤0.01% |
426,369
+3,555
| +0.8% | +$53.6K |
|
|
KYNB
2314
Kyntra Bio
KYNB
$28.5M
| $5.64M | ﹤0.01% |
22,073
-11,045
| -33% | -$3.91M |
|
|
TVRD
2315
Tvardi Therapeutics
TVRD
$22.1M
| $5.63M | ﹤0.01% |
10,125
+230
| +2% | +$115K |
|
|
KREF
2316
KKR Real Estate Finance Trust
KREF
$502M
| $5.63M | ﹤0.01% |
266,526
+65,866
| +33% | +$1.4M |
|
2317
Advantage Solutions
ADV
$423M
| $5.62M | ﹤0.01% |
25,983
-713
| -3% | -$167K |
|
2318
Wheels Up
UP
$187M
| $5.61M | ﹤0.01% |
+4,254
| New | +$6.98M |
|
2319
uniQure
QURE
$3.26B
| $5.61M | ﹤0.01% |
175,138
-7,715
| -4% | -$235K |
|
2320
Univest Financial
UVSP
$1.19B
| $5.6M | ﹤0.01% |
204,599
+1,618
| +0.8% | +$43.4K |
|
|
HNGR
2321
DELISTED
Hanger Inc.
HNGR
| $5.59M | ﹤0.01% |
254,665
-6,765
| -3% | -$157K |
|
|
CCXI
2322
DELISTED
ChemoCentryx, Inc.
CCXI
| $5.58M | ﹤0.01% |
326,433
-26,705
| -8% | -$416K |
|
2323
PMV Pharmaceuticals
PMVP
$65.1M
| $5.58M | ﹤0.01% |
187,163
+72,875
| +64% | +$2.33M |
|
2324
Nicolet Bankshares
NIC
$3.73B
| $5.57M | ﹤0.01% |
75,141
+13,795
| +22% | +$1.01M |
|
2325
KE Holdings
BEKE
$18.7B
| $5.57M | ﹤0.01% |
305,159
+6,500
| +2% | +$158K |
|
Similar funds
Charles Schwab's Q3 2021 Portfolio in Review
As of Q3 2021, Charles Schwab held 3,610 positions worth $306B, up 1.6% from $301B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q3 2021 filing shows 202 new, 2,185 increased, 922 reduced and 109 closed positions. Its largest new stake was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M. The largest sale was Vanguard FTSE Emerging Markets ETF, an estimated $210M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q3 2021 buy was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M.
- Charles Schwab added most to Moderna in Q3 2021, an estimated $269M increase.
- Charles Schwab's biggest Q3 2021 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $210M.
- Charles Schwab fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $195M.
- Charles Schwab's ten largest holdings make up 17% of its $306B portfolio in Q3 2021.
- Charles Schwab opened 202 new positions and closed 109 in Q3 2021.
- Charles Schwab's portfolio value rose 1.6% quarter-over-quarter to $306B.
Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.